The company starts
Cilo Cybin Pharmaceutical is established in South Africa to pursue regulated medical cannabis cultivation and pharmaceutical manufacturing rather than informal extract supply.
About Cilo Cybin
From South Africa's first GACP cannabis licence to the JSE Main Board.
Cilo Cybin Pharmaceutical began as a regulated medical cannabis pioneer and grew into a vertically integrated cannabinoid pharmaceutical platform with GACP cultivation, GMP manufacturing, and listed-company governance.
Origin story
A South African cannabis pharmaceutical company built before the market was obvious.
Cilo Cybin Pharmaceutical was established in 2018, at a time when South Africa's regulated medical cannabis industry was still being defined. The company was built with a simple conviction: cannabis would only become a serious medical and pharmaceutical category if it could be cultivated, processed, documented, and released through controlled systems.
In 2020, Cilo Cybin Pharmaceutical obtained South Africa's first Good Agricultural and Collection Practices (GACP) licence to cultivate medical cannabis. That licence gave the company a regulated foundation for producing traceable source material for downstream pharmaceutical manufacturing.
By 2021, the business had developed into South Africa's first fully vertically integrated cannabis company with both GACP cultivation and GMP manufacturing licences. The platform brought cultivation, extraction, refinement, formulation, packaging, quality control, and commercial supply into one accountable operating model.
Capital markets
From AltX entry to the JSE Main Board.
In 2024, Cilo Cybin Holdings entered the public markets through an AltX listing as a medical-cannabis-focused SPAC structure. The listing created a public-company platform around a regulated pharmaceutical cannabis operating business.
In 2025, the group transitioned from AltX to the JSE Main Board. That move strengthened the public-market profile of the business and positioned Cilo Cybin as a listed pharmaceutical cannabis platform with governance, reporting discipline, and regulated manufacturing capability.
The significance is not only the listing itself. It is the combination of public-company oversight with a vertically integrated GACP and GMP operating base: cultivation, extraction, refinement, formulation, packaging, quality review, and partner supply under one controlled platform.
Company journey
A regulated cannabis story told through milestones.
First GACP cultivation licence
The company obtains South Africa's first GACP medical cannabis cultivation licence, creating a compliant agricultural foundation for medicinal cannabis production.
Vertical integration becomes the model
Cilo Cybin becomes the first fully vertically integrated South African cannabis company with both GACP cultivation and GMP manufacturing licences. International attention followed as Bloomberg covered the emergence of South Africa's legal medical cannabis crop.
AltX listing
Cilo Cybin Holdings lists as a medical-cannabis-focused SPAC on AltX, bringing the operating platform into a public-market structure.
JSE Main Board
The group transitions to the JSE Main Board, becoming a listed pharmaceutical cannabis platform with public governance and regulated manufacturing capability.
Pharmaceutical cannabis focus
Cilo Cybin operates as a JSE-listed pharmaceutical platform focused on regulated cannabis-derived API's, bulk ingredients, finished products, and partner manufacturing.
Current platform
The story now is execution: quality, supply, and partner trust.
Today, Cilo Cybin's value sits in the connection between cultivation, GMP manufacturing, API production, finished-product development, and listed-company discipline. The business is positioned for licensed partners that need cannabinoid products manufactured with traceability, documentation, and repeatable quality controls.
The leadership team brings experience across pharmaceutical manufacturing, cannabis operations, quality management, commercial execution, and regulated-company governance, supported by partnerships that extend technical capability and international market reach.
Company structure
Cilo Cybin operates through a listed holding company and a regulated pharmaceutical operating company.
The public-company layer and the GMP operating layer are connected, but they serve different roles. Holdings provides listed-company governance and shareholder reporting. Pharmaceutical carries the regulated cultivation, manufacturing, product, and partner-supply capability.
Listed holding company
Cilo Cybin Holdings
Cilo Cybin Holdings is the listed holding-company platform for the group. It provides public-company governance, shareholder reporting, capital-markets discipline, and oversight for the regulated pharmaceutical cannabis operating platform.
- Legal entity
- Cilo Cybin Holdings Ltd
- Board records
- 7 directors listed
Operating pharmaceutical company
Cilo Cybin Pharmaceutical
Cilo Cybin Pharmaceutical is the operating company behind the regulated cannabis platform. It houses the GACP cultivation and GMP manufacturing capability used for extraction, refinement, API production, formulation, packaging, quality review, and partner supply.
- Legal entity
- Cilo Cybin Pharmaceutical (Pty) Ltd
- Board records
- 4 directors listed
Holdings sub-committees
Board committee links
Holdings committee membership is shown from the same investor relations source as the board profile records.
Explore the platform
Continue through the Cilo Cybin company story.
Review the people, governance, cultivation base, and GMP manufacturing capability behind the pharmaceutical cannabis platform.